AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN

1. AstraZeneca accused of misleading shareholders about operations in China. 2. Claims include insurance fraud and detainment of the China President. 3. Class action period spans February 23, 2022 to December 17, 2024. 4. Shareholders encouraged to register for possible lead plaintiff role. 5. Legal exposure may significantly impact AZN's business in China.

Legal

75

4m saved

Insight

Article

FAQ

Why Bearish?

The legal issues could lower investor confidence and stock value, similar to cases with other firms in the past facing allegations of fraud.

How important is it?

Legal challenges often negatively affect stock prices, especially in high-risk markets like China.

Why Short Term?

Immediate legal uncertainties can influence stock performance quickly, as seen with prior class actions in similar scenarios.

Related Companies

AZN BMY JNJ

NOTICE TO SHAREHOLDERS OF ASTRAZENECA PLC

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).

Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=128933&from=4

CLASS PERIOD:

February 23, 2022 to December 17, 2024

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; (4) the foregoing, once revealed, could materially harm AstraZeneca's business activities in China; and (5) as a result, defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

DEADLINE:

February 21, 2025. Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=128933&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of AZN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is February 21, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

SOURCE The Gross Law Firm